Company Overview and News

 
BRIEF-Radient Technologies Finalizes Real Estate Transactions For Expansion

2018-04-18 reuters
* RADIENT TECHNOLOGIES - PURSUANT TO JV DEAL, CO AGREED TO ISSUE 1.3 MILLION SHARES, AT DEEMED PRICE OF $1.40, TO VENDOR FOR 100% OWNERSHIP IN JV

 
Radient Technologies Inc. Finalizes Real Estate Transactions for Expansion and Provides Corporate Update

2018-04-18 globenewswire
EDMONTON, Alberta, April 18, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce the following update on its operations and 2018 growth initiatives.

2
A Look at Aurora Cannabis’s Partnerships

2018-04-06 editors.aws.marketrealist
Aurora Cannabis (ACB) (ACBFF), similar to Canopy Growth (WEED), has made several investments over the last two years.

1
Aurora Cannabis Inc. Kills It In The Last Quarter - More To Come

2018-02-12 seekingalpha
Aurora Cannabis Inc. (OTCQX:ACBFF) generated terrific numbers in the last quarter, with revenues soaring by over 200 percent over the same reporting period in 2016.

 
ABcann Global Is A Potentially Strong Play In Cannabis

2018-02-04 seekingalpha
ABcann Global Corp. (OTCQB:ABCCF) has carved out a niche in the cannabis market by producing consistent, high-quality medical pot from its base in Napanee, Canada.

1
261 Marijuana Stocks: Jeff Slowed Us Down, But 32% In Less Than 30 Days Is Not Bad

2018-01-30 seekingalpha
In January 2017, the cannabis or marijuana stocks and sector generated a return of about 51%.

1
Cannabis Stocks: Not A Dot-Com Bubble...Yet

2018-01-25 seekingalpha
The cannabis stocks have been on a tear and people are worried there is too much speculation in the market. Investors are afraid to buy and scared to sell.

1
Cannabis Production And Radient Technologies Go Together Like Peanut Butter And Jelly

2018-01-18 seekingalpha
Radient's technology increases extraction yields from products which will be highly desired in the growing cannabis market.

 
Get Out Your Picks And Shovels: Ancillary Plays On Cannabis

2018-01-18 seekingalpha
Cannabis Wheaton Income is using a unique financing method to accelerate the growth of the industry.

 
Radient Technologies Inc. Reiterates its Non-Exposure to U.S. Marijuna-Related Activity

2018-01-15 marketwired
EDMONTON, ALBERTA--(Marketwired - Jan. 15, 2018) - In response to the January 12, 2018 statement issued by the Canadian Securities Administrators ("CSA") in which the CSA stated it "is considering whether [its] disclosure-based approach for issuers with U.S. marijuana-related activities remains appropriate in light of the rescission of the Cole Memorandum," Radient Technologies Inc. ("Radient" or the "Corporation") (TSX VENTURE:RTI) wishes to reiterate that its business development, operational, and capital markets activity is currently conducted only where its actions are federally legal, and in compliance with all other applicable laws.

 
Radient Technologies Inc. Provides Corporate Update and Announces Real Estate Expansion

2018-01-09 marketwired
EDMONTON, ALBERTA and CALGARY, ALBERTA--(Marketwired - Jan. 9, 2018) - Radient Technologies Inc. ("Radient" or the "Corporation") (TSX VENTURE:RTI) is pleased to provide the following update on its operations and 2018 growth initiatives.

4
Canadian Cannabis Stocks: 2018 Outlook

2018-01-03 seekingalpha
Canadian cannabis stocks had a positive year in 2017 with the Let's Toke Business Marijuana Composite posting a return of.21.7% and the LTB Licensed Producer Index recording a return of.46.0%.

 
Radient Technologies Inc. Announces Master Services Agreement with Terra Life Sciences

2017-12-12 marketwired
EDMONTON, ALBERTA and CALGARY, ALBERTA--(Marketwired - Dec. 11, 2017) - Radient Technologies Inc. ("Radient" or the "Corporation") (TSX VENTURE:RTI) announces the signing of a Master Services Agreement (the "Agreement") to produce cannabis extracts for the Terra Life Sciences group ("Terra Life Sciences"), a private, Alberta-based pharmaceutical manufacturer whose ACMPR license is expected in the near future.

 
Radient Technologies Inc. Announces Executive Appointments, Options Grant, and Shares for Services Agreement

2017-12-06 marketwired
EDMONTON, ALBERTA--(Marketwired - Dec. 6, 2017) - Radient Technologies Inc. ("Radient" or the "Corporation") (TSX VENTURE:RTI) is pleased to announce the senior appointments (the "Appointments") of Jim Seethram and Dr. Tomasz Popek to key roles in its growth plans.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...